Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Fish oil placebo

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    16 result(s) found for: Fish oil placebo. Displaying page 1 of 1.
    EudraCT Number: 2015-003147-19 Sponsor Protocol Number: BECRO/MINERALstudy Start Date*: 2016-07-18
    Sponsor Name:PALUPA Medical Ltd
    Full Title: Novel Oral Nutraceutical Intervention NEUROASPIS PLP10® for the Treatment of Relapsing-Remitting Multiple Sclerosis: A Multicenter, Parallel-group, Phase III, Double-blind, Randomized, Placebo-Cont...
    Medical condition: Relapsing-Remitting Multiple Sclerosis (RRMS)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-002688-10 Sponsor Protocol Number: 05/S1401/62 Start Date*: 2005-08-31
    Sponsor Name:University of Dundee
    Full Title: The Effect of omega-3 polyunsaturated Fatty Acid Supplements on Microvolt T-Alternans in Patients with Ventricular Arrythmia
    Medical condition: Patients with Implantable Cardioverter Defibrillator(ICD) with ventricular arrythmias
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-002386-37 Sponsor Protocol Number: IVN3ICD Start Date*: 2007-08-24
    Sponsor Name:Department of Cardiology, Aalborg Hospital
    Full Title: Intravenous infusion of n-3 polyunsaturated fatty acids and ventricular tackycardi in patients with implantable cardioverter defibrillator (ICD)
    Medical condition: Patients with an implantable cardioverter defibrillator (ICD-unit) for treatment for cardiac ventricular arrhythmias and for prevention of sudden cardiac death
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-011106-42 Sponsor Protocol Number: 2008MZ09B Start Date*: 2009-06-25
    Sponsor Name:Institute for Clinical and Experimental Medicine
    Full Title: Aditive effects of omega-3 polyunsaturated fatty acids and pioglitazone in the treatment of type 2 diabetes mellitus
    Medical condition: The project deals with hummoral and metabolic aspects of insulin resistance (IR), which is assumed to be the basic metabolic disorder which leads to the development of type 2 diabetes mellitus (T2D...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002293-28 Sponsor Protocol Number: 2020-002293-28 Start Date*: 2020-05-29
    Sponsor Name:Karolinska University Hospital
    Full Title: Resolving inflammatory storm in COVID-19 patients by Omega-3 polyunsaturated fatty acids. - A single-blind, randomized, placebo-controlled feasibility study
    Medical condition: SARS-COV-2 Infection
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10084272 SARS-CoV-2 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-003853-13 Sponsor Protocol Number: HPEPA-01 Start Date*: 2005-01-13
    Sponsor Name:Hela Pharma AB
    Full Title: Placebo controlled, randomised, double-blind, multicentre study of PlusEPA (a PUFA, Polyunsaturated Fatty Acids, supplement) as treatment for ADHD (combined type) with co-morbidity in Swedish child...
    Medical condition: ADHD (combined type) and co-morbidity in children
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-000872-40 Sponsor Protocol Number: CLCQ908C2201 Start Date*: 2012-11-13
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A pilot study to assess the efficacy and safety of LCQ908 alone and in combination with fenofibrate or Lovaza® in patients with severe hypertriglyceridemia
    Medical condition: Non Familial Chylomicronemia Syndrome (Non-FCS)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10020870 Hypertriglyceridemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-001921-86 Sponsor Protocol Number: S185.4.001 Start Date*: 2007-07-19
    Sponsor Name:Solvay Pharmaceuticals GmbH
    Full Title: A double-blind, placebo-controlled, parallel-group, multi-center study to investigate the effect of Omacor (n-3 PUFA) on lipid parameters in HIV infected patients treated with HAART
    Medical condition: HAART-induced hypertriglyeridemia in HIV infected subjects
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020869 Hypertriglyceridaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-003503-39 Sponsor Protocol Number: ABR54654 Start Date*: 2016-07-27
    Sponsor Name:University Medical Center Utrecht
    Full Title: Placebo-controlled Trial in Subjects at Ultra-high Risk for Psychosis With Omega-3 Fatty Acids in Europe
    Medical condition: Individuals at Ultra High Risk for Psychosis
    Disease:
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed) AT (Completed) IT (Completed) ES (Ongoing) DE (Completed) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2009-014868-19 Sponsor Protocol Number: AKTN06.01 Start Date*: 2011-08-19
    Sponsor Name:Australian Kidney Trials Network, University of Queensland
    Full Title: A randomised, double-blind, placebo-controlled, factorial-design trial to assess the effect of aspirin & fish oil in the prevention of early thrombosis in arterio-venous fistulae in patients with S...
    Medical condition: Prevention of early thrombosis in arterio-venous fistulae in patients with Stage IV or V chronic kidney disease requiring haemodialysis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10042613 - Surgical and medical procedures 10060478 Thrombosis prophylaxis in haemodialysis LLT
    14.0 10022117 - Injury, poisoning and procedural complications 10059336 Haemodialysis fistula thrombosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2016-004970-16 Sponsor Protocol Number: CS15-033 Start Date*: 2017-05-30
    Sponsor Name:Medizinische Universität Wien
    Full Title: Imaging the functional and molecular impact of poly-unsaturated fatty acids on dopamine-dependent cognitive functions: a combined [11C]-(+)-PHNO PET/MRI study at different stages of cognitive impai...
    Medical condition: This study will assess the effects of poly-unsaturated fatty acids on working memory (measured using an n-back test) in healthy volunteers, in subjects who are at high risk for developing a psychot...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039628 Schizophrenia and other psychotic disorders HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-003107-29 Sponsor Protocol Number: N°005 Start Date*: 2015-08-07
    Sponsor Name:GALMED Pharmaceuticals LTD.
    Full Title: A Phase IIb, double blind, randomized controlled clinical trial to evaluate the efficacy and safety of two Aramchol doses versus placebo in patients with Non-Alcoholic- Steatohepatitis (NASH).
    Medical condition: Non-alcoholic Steatohepatitis in patients with two additional features of metabolic syndrome -overweight or obesity and Diabetes Mellitus type II or pre-diabetes.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) RO (Ongoing) LT (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-003373-18 Sponsor Protocol Number: ISIS681257-CS6 Start Date*: 2017-06-28
    Sponsor Name:Akcea Therapeutics, Inc.
    Full Title: A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Phase 2 Study of ISIS 681257 Administered Subcutaneously to Patients with Hyperlipoproteinemia(a) and Established Cardiovascular Disease...
    Medical condition: Hyperlipoproteinemia(a) and Established Cardiovascular Disease (CVD)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10020668 Hyperlipoproteinemia LLT
    20.1 100000004849 10007648 Cardiovascular disease, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2020-000641-13 Sponsor Protocol Number: BIO89-100-221 Start Date*: 2020-09-30
    Sponsor Name:89bio, Inc.
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Explore the Efficacy and Safety of BIO89-100 in Subjects with Severe Hypertriglyceridemia
    Medical condition: Severe Hypertriglyceridemia (SHTG)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10020870 Hypertriglyceridemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2009-010067-16 Sponsor Protocol Number: CN156018 Start Date*: 2009-07-08
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of BMS-708163 in the Treatment of Patients with Prodromal ...
    Medical condition: ALZHEIMER DISEASE
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed) NL (Completed) FR (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-010520-25 Sponsor Protocol Number: AMR-01-01-0016 Start Date*: 2009-12-08
    Sponsor Name:Amarin Pharma Inc.
    Full Title: A Phase 3, Multi-Center, Placebo-Controlled, Randomized, Double-Blind, 12-Week Study With an Open-Label Extension to Evaluate the Efficacy and Safety of AMR101 in Patients With Fasting Triglycer...
    Medical condition: Hypertriglyceridemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10014486 Elevated triglycerides HLT
    9.1 10020870 Hypertriglyceridemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) DK (Prematurely Ended) FI (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 15 10:17:02 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA